Plasma transforming growth factor-beta1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study. - Wikidata - wikimedia - TriplyDB

Plasma transforming growth factor-beta1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study.

Plasma transforming growth factor-beta1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study.

http://www.wikidata.org/entity/Q43742730

about

Antioxidant supplements for liver diseases Antioxidant supplements for non-alcoholic fatty liver disease and/or steatohepatitis Nonalcoholic fatty liver disease Treatment of non-alcoholic fatty liver disease Vitamin C and vitamin E in prevention of Nonalcoholic Fatty Liver Disease (NAFLD) in choline deficient diet fed rats Measurement of the total antioxidant response using a novel automated method in subjects with nonalcoholic steatohepatitis.Pathophysiology guided treatment of nonalcoholic steatohepatitis Role of cytokines and chemokines in non-alcoholic fatty liver disease Dietary habits and behaviors associated with nonalcoholic fatty liver disease Prevention of hepatocellular carcinoma: Focusing on antioxidant therapy Vitamin E and nonalcoholic fatty liver disease Immune Imbalances in Non-Alcoholic Fatty Liver Disease: From General Biomarkers and Neutrophils to Interleukin-17 Axis Activation and New Therapeutic Targets Mediterranean diet and nonalcoholic fatty liver disease: molecular mechanisms of protection.Non-alcoholic Fatty Liver Disease and Metabolic Syndrome-Position Paper of the Indian National Association for the Study of the Liver, Endocrine Society of India, Indian College of Cardiology and Indian Society of Gastroenterology.High-dose vitamin E supplementation does not diminish ribavirin-associated haemolysis in hepatitis C treatment with combination standard alpha-interferon and ribavirin.Inhibitory effect of angiotensin II receptor antagonist on hepatic stellate cell activation in non-alcoholic steatohepatitis Mechanisms inactivating the gene for E-cadherin in sporadic gastric carcinomas.Is there an effective therapy available for non-alcoholic fatty liver disease?Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design.Treatment of nonalcoholic fatty liver disease in children: TONIC trial design.Treatment options for nonalcoholic Fatty liver disease Management of nonalcoholic fatty liver disease: an evidence-based clinical practice review.Pathogenesis and therapeutic approaches for non-alcoholic fatty liver disease The use of selected nutrition supplements and complementary and alternative medicine in liver disease.Treatment of non-alcoholic fatty liver disease.Nonalcoholic Fatty liver disease and obesity.Hypertension and fatty liver: guilty by association?Anti-inflammatory and anti-fibrotic profile of fish oil emulsions used in parenteral nutrition-associated liver disease.Nonalcoholic steatohepatitis: what we know in the new millennium.Co-administration of cyclosporine an alleviates thioacetamide-induced liver injury.Review article: Non-alcoholic fatty liver disease.Current best treatment for non-alcoholic fatty liver disease.Nutrition and physical activity in NAFLD: an overview of the epidemiological evidence.Non-alcoholic fatty liver disease: The diagnosis and management.A new approach to drug therapy in non-alcoholic steatohepatitis (NASH).Metabolic syndrome and hepatic resection: improving outcome Hepatic steatosis in obese patients: clinical aspects and prognostic significance.Non-alcoholic steatohepatitis in the Asia-Pacific region: future shock?Fatty liver disease in children.Plasma levels of vitamin E and carotenoids are decreased in patients with Nonalcoholic Steatohepatitis (NASH).

P2860

Q24235796-90A4C805-AB23-4659-8BCA-03B5B26EC3D6 Q24243125-5B15C024-72DD-4B94-99E0-492D161A0C70 Q24555779-01911C10-F8B5-426F-923C-145679848D71 Q24655572-77ADFB0E-F01A-4228-A6B8-A1A9C10C5319 Q24791727-29456A19-2A5B-413F-9B0C-333A7A5653EE Q24815160-5C24F3BE-351D-4637-B7C3-4240E01D182C Q26827117-9F5FDB65-142D-486F-89A0-B30E3521077D Q26830328-21BD9839-59CC-40B5-A18D-CBC173F93C74 Q26830594-7016A05F-78C1-4571-AF4F-FC2374B3582D Q26853520-2A645E8E-1058-48C6-999F-092C4137C21F Q27693883-0F235269-B7A7-4E97-B494-899C10957B31 Q28079713-5573CB85-21AE-4966-AC71-EA1976EB2B58 Q30248650-072C22AE-1EE5-498A-9A8E-E83C70D6EC63 Q30389752-DD4585FE-8A4E-40BA-B9E8-A3BCB36A085C Q33209400-5F1D2245-0960-4BD2-9F40-2F3FB83B563E Q33788174-865B154B-D79C-40AF-881F-49341E7CC059 Q33867088-0A7587D8-7297-478D-A904-C517C0BCDB2F Q34076451-6D1EB995-A50C-4CB6-8077-1799BF80E45A Q34090872-6B7008C6-16E6-4A75-BE1C-4D22B841D5A2 Q34114795-1058C7D9-0458-474E-A221-30D3F45BC36A Q34156317-FA7967C0-59B0-42FD-B9D9-546904B50AF7 Q34168532-31EF16CC-B549-4ACC-B19E-ED5C246FB163 Q34449857-E5A89BB9-52FA-4A15-925F-631B1CCDDB2B Q34554574-2AA806EF-F8DE-420A-B858-BAF01CF49719 Q34592654-EF0D1ED8-5994-429E-A4A1-12058A406E0B Q34605022-08C372B1-79EC-422E-B18B-7316D1995150 Q34608817-840F0489-EDC0-4F6A-9855-CF22FC7AED0A Q34691490-9AF9B424-280B-4E3C-9133-DAE2A9E7E431 Q34993711-3FAA6DCA-4D44-4826-AE22-6B2834293094 Q35010389-6CE65A1C-EC29-476A-85BA-DC541CF5C03C Q35106643-72B2A2DE-08A5-4B2B-9304-B3FC746DE9C0 Q35124679-5105ED1F-F26F-4E66-970B-C92560751D60 Q35178073-BC094628-77AE-46C1-AD15-A05F17CA4F2D Q35543956-5B7EEF91-CF9E-4B22-94ED-720D662B964F Q35621565-15834194-C061-4284-9D98-A4121E429059 Q35629684-1C33526D-120E-4F9F-A414-C90A737B734E Q35669794-F82CA400-F2FE-4536-A13B-0822185BAF4D Q35687669-3A846453-325A-40D5-B888-76FCACDA7F6F Q35813390-FD549CC9-4ED8-402B-AFAB-0C2E08718D8B Q35963951-64F3342F-9FA4-4F0C-A25B-98C1621A9868

P2860

Plasma transforming growth factor-beta1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study.

http://www.wikidata.org/entity/Q43742730

description

2001 nî lūn-bûn

@nan

2001年の論文

@ja

2001年学术文章

@wuu

2001年学术文章

@zh

2001年学术文章

@zh-cn

2001年学术文章

@zh-hans

2001年学术文章

@zh-my

2001年学术文章

@zh-sg

2001年學術文章

@yue

2001年學術文章

@zh-hant

name

Plasma transforming growth fac ...... teatohepatitis: a pilot study.

@en

Plasma transforming growth fac ...... teatohepatitis: a pilot study.

@nl

type

label

Plasma transforming growth fac ...... teatohepatitis: a pilot study.

@en

Plasma transforming growth fac ...... teatohepatitis: a pilot study.

@nl

prefLabel

Plasma transforming growth fac ...... teatohepatitis: a pilot study.

@en

Plasma transforming growth fac ...... teatohepatitis: a pilot study.

@nl

P1433

Q43742730-2E0ACAE1-6C7C-4E6D-808D-66B5D2D88B19

P1476

Q43742730-51CB9620-4FA6-4EF6-B729-E9E0AC4DB3FA

P2093

Q43742730-96702AA7-089C-4C68-B69E-B17F8B0E4368

Q43742730-B2EE13E9-8BC3-4467-AF31-71D5972B4E2F

Q43742730-D26156A8-9680-4059-8390-F2E50CD2A6D3

Q43742730-DBF64E69-B208-441E-9C9B-9E33F84845CC

Q43742730-FE1F90D9-DF50-4D5B-8255-1A1E52BCC4FF

P2860

Q43742730-08B63E18-C5C7-4836-8CD0-89B85406602C

Q43742730-0C65A77F-ED39-439F-B402-EF60FFF2997F

Q43742730-6E0C0368-6C09-4400-9D81-23852CC9974D

Q43742730-71B9D922-3ED5-49ED-B805-EA2A362A5F60

Q43742730-7B1F3A0E-3CA6-4B48-825A-7ED14E999389

Q43742730-7FC1F3CE-775C-408A-945B-18C3BA4EE04C

Q43742730-80DEF274-98F9-4EDB-9F2A-AE2594020CD3

Q43742730-869B41DC-BD76-474D-95CE-B62EEFB86955

Q43742730-96ED52A8-DEBF-4295-B8A0-F4188B19F5F1

Q43742730-9A665E91-C4D9-4047-BE06-E64901755556

P304

Q43742730-1D40E45D-9943-4C07-BD30-27F03558677A

P31

Q43742730-7F53C3AC-6ACD-4DF7-B2C0-A4E5A2B92EE7

P356

Q43742730-3DFCFC57-1AFB-49AF-A4DB-52CCC3A7BB15

P407

Q43742730-2A2C37C9-DB06-423F-BDB6-5D97DA4A035C

P433

Q43742730-F626B275-3FEF-44BA-8CD1-8545A2E07216

P478

Q43742730-937F6B80-B607-44A7-B8DB-50B64087C13F

P577

Q43742730-4A1AC79E-2192-4DEF-8805-1B0B8CDBB37D

P5875

Q43742730-027A1D13-8512-46D4-824B-C19FAF0AADAD

P698

Q43742730-EC6FA27A-DE57-438A-9531-CF1529C0D148

P921

Q43742730-40CCA491-6E5C-4420-9B0D-061BB75EA4EE

P356

J.1365-2036.2001.01083.X

P1433

Alimentary Pharmacology & Therapeutics

P1476

Plasma transforming growth fac ...... teatohepatitis: a pilot study.

@en

P2093

Hasegawa T

http://www.w3.org/2001/XMLSchema#string

Makino I

http://www.w3.org/2001/XMLSchema#string

Nakamura K

http://www.w3.org/2001/XMLSchema#string

Terano A

http://www.w3.org/2001/XMLSchema#string

Yoneda M

http://www.w3.org/2001/XMLSchema#string

P2860

Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis

Hepatic expression of mature transforming growth factor beta 1 in transgenic mice results in multiple tissue lesions.

In vitro and in vivo association of transforming growth factor-beta 1 with hepatic fibrosis

Induction of apoptosis in cultured hepatocytes and in regressing liver by transforming growth factor beta 1.

Stimulation of hepatic lipocyte collagen production by Kupffer cell-derived transforming growth factor beta: implication for a pathogenetic role in alcoholic liver fibrogenesis.

Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study.

Liver investigation in 149 asymptomatic patients with moderately elevated activities of serum aminotransferases.

The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years.

Hepatic effects of dietary weight loss in morbidly obese subjects.

Effect of weight reduction on hepatic abnormalities in overweight patients.

P304

1667-1672

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1046/J.1365-2036.2001.01083.X

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P577

2001-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11784057

http://www.w3.org/2001/XMLSchema#string

P698

11564008

http://www.w3.org/2001/XMLSchema#string

P921

Steatohepatitis